PRCT
PROCEPT BioRobotics CorporationNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
3.83
P/S
4.60
EV/EBITDA
-14.75
DCF Value
$46.50
FCF Yield
-4.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
63.7%
Operating Margin
-33.7%
Net Margin
-31.0%
ROE
-25.1%
ROA
-18.8%
ROIC
-23.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $76.4M | $-29.8M | $-0.54 |
| FY 2025 | $308.1M | $-95.6M | $-1.72 |
| Q3 2025 | $83.3M | $-21.4M | $-0.38 |
| Q2 2025 | $79.2M | $-19.6M | $-0.35 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.93
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.